News

NEWS

7th February, 2020


Pedanius Therapeutics to present at the 2020 BioInfect Conference




Read on

27th January, 2020


Pedanius Therapeutics LepB, RpsJ and LptD programmes demonstrates in vivo efficacy in Pneumonia caused by P. aeruginosa


Read on

10th January 2020


TheraIndx Lifesciences successfully delivers in vivo Pharmacology for Pedanius Therapeutics SBRI Contract to Tackle Antimicrobial Resistance in Humans 


Read on

6th December, 2019


Pedanius Therapeutics AcpP programme demonstrates in vivo efficacy in UTI caused by E. coli



Read on

13th December, 2019


Pedanius Therapeutics FtsZ programme demonstrates in vivo efficacy in Pneumonia caused by A. baumannii



Read on

28th November, 2019


Pedanius Therapeutics announces filing of an International PCT patent application relating to new bacterial RNA-targeted therapeutics


Read on

28th June, 2019


Key Organics successfully delivers Chemistry for Pedanius Therapeutics SBRI Contract to Tackle Antimicrobial Resistance in Humans 



Read on

22nd February, 2019


Pedanius Therapeutics secures £499,532 SBRI Contract to Tackle Antimicrobial Resistance in Humans

.


Read on

29th March, 2019


Pedanius Therapeutics announces a NBIC funded research collaboration with the University of Nottingham to tackle biofilms



Read on

16th February, 2019


Pedanius Therapeutics announces filing of a patent application relating to new bacterial RNA-targeted therapeutics



Read on

14th March, 2019


Pedanius Therapeutics presents at 

12th Berlin Conference on Life Sciences Novel Antimicrobials and AMR Diagnostics 2019



Read on

info@pedaniustherapeutics.com

 

BioHub, Alderley Park, UK

 

Incorporated in England and Wales with registered number 11249269